Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer | Zendy

Sara M. Tolaney | Zendy; William T. Barry | Zendy; Chau T. Dang | Zendy; Denise A. Yardley | Zendy; Beverly Moy | Zendy; P. Kelly Marcom | Zendy; Kathy S. Albain | Zendy; Hope S. Rugo | Zendy; Matthew J. Ellis | Zendy; Iuliana Shapira | Zendy; Antonio C. Wolff | Zendy; Lisa A. Carey | Zendy; Beth Overmoyer | Zendy; Ann H. Partridge | Zendy; Hao Guo | Zendy; Clifford A. Hudis | Zendy; Ian E. Krop | Zendy; Harold J. Burstein | Zendy; Eric P. Winer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Author(s) -

Sara M. Tolaney,

William T. Barry,

Chau T. Dang,

Denise A. Yardley,

Beverly Moy,

P. Kelly Marcom,

Kathy S. Albain,

Hope S. Rugo,

Matthew J. Ellis,

Iuliana Shapira,

Antonio C. Wolff,

Lisa A. Carey,

Beth Overmoyer,

Ann H. Partridge,

Hao Guo,

Clifford A. Hudis,

Ian E. Krop,

Harold J. Burstein,

Eric P. Winer

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1406281

Subject(s) - trastuzumab , medicine , breast cancer , oncology , adjuvant , paclitaxel , human epidermal growth factor receptor 2 , cancer

No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research